Articles On Imugene (ASX:IMU)

Alloggio Group (ASX:ALO), didn’t have a positive debut on the ASX last week but that didn’t stop one director from buying more on market. The holiday accommodation manager listed at 20 cents per share but fell as low as 15 cents on debut am...

Today, the S&P/ASX 200 Index (ASX: XJO) made an effort to recoup its early morning losses but was unable to overcome the downward pressure. At the end of the session, the benchmark index finished 0.15% lower to 7,225.2 points. While th...

The ASX 200 closed in the red for the third time in four sessions on Thursday, but an afternoon rally saw it finish just 0.15% lower on the day. As markets reassess the outlook for tighter monetary policy and ongoing COVID-19 disruptions, t...

Today, the S&P/ASX 200 Index (ASX: XJO) partially bounced back from yesterday’s Omicron-induced panic. At the end of the session, the benchmark index finished 0.22% higher to 7,256 points. The gains were far-reaching across the Aussie...

After climbing more than 1% in morning trade, local large caps lost ground in the afternoon session as the ASX 200 finished up eking out a 0.22% gain. The big end of town was clearly outshone by the microcap Emerging Companies index, which...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

The Imugene Limited (ASX: IMU) share price is flat at 52.5 cents in early trade today after finishing 4.5% in the red yesterday. However, shares in the biopharma company have climbed 17% in the past month. They are also up 81% since the...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

After falling by ~0.8% on Tuesday, the ASX 200 struggled for traction in Wednesday trade to finish 0.15%. Now that he’s shepherded the US economy through a pandemic, J-Pow is back for a second term. And while he’s not about to hike rates wi...

As Stockhead’s Josh Chiat reported this morning, reports of an industrial production slowdown in the Middle Kingdom may have been greatly exaggerated. In fact, the latest update from the People’s Bank of China raised the possibility to more...

The success of trials of the company's cancer immunotherapy drug to date has encouraged Roth Capital Partners to place a buy recommendation and raise Imugene's price target to A$0.71 from A$0.62.

Today, the S&P/ASX 200 Index (ASX: XJO) managed to deliver a positive session despite weakness in markets overnight. At the end of the day, the benchmark index finished 0.13% higher at 7,379.2 points. Despite another lacklustre day for...

The ASX 200 rebounded by 0.13% today, after posting losses over the last two days. Healthcare, Real Estate and Consumer Staples were the best sectors rising by 1% each, while Energy was the main laggard losing 1%. Falls in energy stocks fol...

Imugene (ASX:IMU) has announced a new supply agreement with Pfizer and Merck for a trial involving their PBS-listed PD-L1 BAVENCIO (avelumab).

The ASX 200 continues its slide, down by 0.63% today after a 0.67% fall yesterday. Stocks were sold off following an ABS data release showing a 3.4% surge in white collar salaries in the year ending September. Overall wages also rose 2.2 pe...

Highlights Imugene shares rose nearly 9% on signing a new clinical trial supply agreement. OZ Minerals’ share price fell even after it hiked its total copper reserve estimates. Resimac Group shares dropped following earnings report fo...

The Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech stock, gained 600% over the last 12 months. The post Imugene Share Price Up on Agreement with Merck and Pfizer (ASX:IMU) appeared first on...

After making a steady start to the week on Monday, the ASX 200 ran into a roadblock on Tuesday to finish ~0.8% lower. Large cap resources stocks led the laggards, as the ASX 200 Materials index fell by more than 1.7%. There were few standou...

Today, the S&P/ASX 200 Index (ASX: XJO) came under pressure as the RBA noted better-than-expected progress towards its inflation target. After the closing bell, the benchmark index was 0.67% lower at 7,420.4 points. Unfortunately, the...

16 Nov 2021 - A snapshot of the stocks on the move, featuring Imugene (ASX:IMU), Beach Energy (ASX:BPT), Woodside Petroleum (ASX:WPL).

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and tumbling lower. At the time of writing, the benchmark index is down 0.7% to 7,416.2 points. Four ASX shares that have not let that hold them back are listed below....

Highlights The ASX 200 had dropped as much as 0.6% by mid-session on Tuesday. Barring A-REIT, all sectoral indices were trading in the red. Mesoblast, Nearmap, Zip Co were among top losers on the ASX. Investors are keeping their eyes...

The ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader index which is down by 0.50%. Imugene (ASX:IMU) was up 4.35% in morning trading, after announcing partnership agreements  with Merck KGaA and Pf...

The Imugene Ltd (ASX: IMU) share price is surging in morning trade, up 9% at time of writing. Below we take a look at the clinical trial supply agreement announced this morning that looks to be driving ASX investor interest. What agreement...

16 Nov 2021 - Bio-tech company Imugene (ASX: IMU) has announced a new clinical trial supply agreement to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a therapeutic cance…

Imugene (IMU) secures a new clinical trial supply agreement with Pfizer Inc and Merck KGaA, Darmstadt to treat patients with HER-2 positive gastric cancer The randomised, Phase 2 clinical trial will evaluate the safety and efficacy of Imug...

“HER-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we are looking forward to evaluating HER-Vaxx with avelumab in the perioperative clinical setting," says...

Wall Street retreats slightly All three US stockmarket benchmarks were slightly lower on Monday – the Dow Jones was down by 0.04%, the S&P500 by 0.01%, and tech heavy Nasdaq by 0.04%. Tesla CEO Elon Musk threatened to sell more of his s...

Highlights The ASX 200 has delivered a return of over 11% so far this year as the domestic economy gradually rebounds. Several businesses have also followed the economic rebound as consumption picks up. Some of the stocks that are on...

Today, the S&P/ASX 200 Index (ASX: XJO) finished the week on a positive note, breaking a four-day red streak. At the end of the session, the benchmark index finished 0.92% higher at 7,449.8 points. The stars aligned for commodities ove...

The ASX 200 finished the week with some strong Friday vibes to close almost 1% higher. It was a commodity-led rally, as investors jumped back into the iron majors and energy stocks also outperformed. Big banks also got a (smaller) bid in th...

Highlights Despite pandemic, few ASX companies have delivered outstanding returns. LTR, ACB, PTX, NVX and IMU have gained over 300% so far. Few ASX listed stocks have given outstanding returns despite the pandemic challenges. Let’...

Today, the S&P/ASX 200 Index (ASX: XJO) has delivered its third consecutive day of gains. At the end of the day, the benchmark index finished 0.39% higher at 7,456.9 points. Only two sectors finished in the red on Friday, with those be...

"Our 12-month price target of A$0.62 is based on a DCF analysis using a 15% discount rate ... We arrive at this valuation by projecting future revenue from CHECKvacc in TNBC, HER-Vaxx in advanced HER2+ gastric cancer, and PD1-Vaxx in NSCLC....

Today, the S&P/ASX 200 Index (ASX: XJO) followed the lead of Wall Street with another positive session. At the end of the trading day, the benchmark index finished 0.48% higher at 7,428 points. Most sectors on the market finished in a...

Local large caps posted a solid day of trade on Thursday, as the ASX 200 finished 0.36% higher. Gains were led by the Information Technology sector, with Square Inc shareholders signing off on the company’s all-share bid for Afterpay (ASX:A...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Today, the S&P/ASX 200 Index (ASX: XJO) delivered a positive session for investors. At the end of the trading day, the benchmark index finished 0.93% higher at 7,392.7 points. It would be a challenge to find a poor-performing company o...

The ASX 200 responded to record high levels on Wall Street overnight, rallying by 0.89% to close at 7,389 points. All eleven sectors were up, led by the miners which gained around 1.5% ahead of the US Fed statement due today (US time). Lith...

Imugene (ASX:IMU) has announced a new collaboration under which it will evaluate its CD19 oncolytic virus onCARlytics technology in combination with Eureka Therapeutic’s anti-CD19 ARTEMIS T-cell therapy for the treatment of solid tu...

Today, the S&P/ASX 200 Index (ASX: XJO) kicked off the new week with a green session. At the end of the trading day, the benchmark index finished 0.64% higher at 7,370.8 points. The markets were awash with gains across all sectors exce...

Following Wall Street’s record levels on Friday, the ASX 200 rebounded to rise by 0.6% today. All sectors were in the green, except for Financials which fell by around 0.6%. The sector was dragged down by Westpac (ASX:WBC), which slumped by...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.8% to 7,382.5 points. Four ASX shares that are climbing more than most today are...

Shares in biotech company Imugene Limited (ASX: IMU) are lifting in afternoon trade today and are changing hands 9.09% higher at 54 cents. Imugene’s share price has been gaining ground today after the company announced a strategic partner...

The ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index which is higher by 0.5%. The US FDA has accepted the New Drug Application (NDA) for Maxigesic IV, AFT Pharma’s (ASX:AFP) intravenous form of...

Imugene (IMU) teams up with US-based Eureka Therapeutics to test a combination of clinical treatments against solid tumours Imugene will combine its onCARlytics technology with Eureka’s ARTEMIS T-cell therapy and test the products’ ability...

The collaboration has the potential to address the lack of tumour-specific targets in solid tumours for T-cell therapies by using oncolytic virus to force tumours to express CD19.